Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer
Our data demonstrate the feasibility of monitoring ctDNA in the postoperative and adjuvant settings in early-stage UC. Analysis of ctDNA, in addition to other risk factors, may help identify patients at the highest risk of recurrence, inform surveillance strategies, and support treatment decision-making for these patients.
Authors
- Luis Vaccarello
- Tara Berman (ORCID: https://orcid.org/0000-0001-5165-0570)
- Minetta C. Liu (ORCID: https://orcid.org/0000-0002-8206-5232)
- Robert W. Holloway (ORCID: https://orcid.org/0000-0002-3121-4605)
- Punashi Dutta (ORCID: https://orcid.org/0000-0002-0166-498X)
- Meenakshi Malhotra (ORCID: https://orcid.org/0000-0002-9731-5628)
- Adam C. ElNaggar (ORCID: https://orcid.org/0000-0003-3409-583X)
- Michael Toboni (ORCID: https://orcid.org/0000-0002-2199-9760)
- Rebecca C. Arend (ORCID: https://orcid.org/0000-0003-2108-3426)
- Nicole Hook (ORCID: https://orcid.org/0000-0002-4284-6042)
- Paul Loar
- Ekaterina Kalashnikova (ORCID: https://orcid.org/0000-0003-1078-0656)
- Carly Bess Scalise (ORCID: https://orcid.org/0000-0002-7612-7791)
- Fernando O. Recio
- Zachary L. Gentry (ORCID: https://orcid.org/0000-0003-3435-8046)
- Peter Ketch (ORCID: https://orcid.org/0000-0003-4770-1579)
Institutions
- Texas Oncology (US)
- University of Alabama at Birmingham (US)
- Florida Hospital Cancer Institute (US)
- Virginia Cancer Institute (US)
- Natera (United States) (US)
- Mark H. Zangmeister Cancer Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1200/po-25-00286
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00